| 李良浩,常颖,郑艺荣.卡格列净联合洛塞那肽对2型糖尿病胰岛素抵抗患者胰岛功能、YKL-40、PPARγ的影响.[J].中南医学科学杂志.,2024,(1):120-122. |
| 卡格列净联合洛塞那肽对2型糖尿病胰岛素抵抗患者胰岛功能、YKL-40、PPARγ的影响 |
| Effects of canagliflozin combined with losenatide on islet function, YKL-40, PPARγ in type 2 diabetes patients with insulin resistance |
| 投稿时间：2023-06-19 修订日期：2023-12-18 |
| DOI：10.15972/j.cnki.43-1509/r.2024.01.029 |
| 中文关键词: 卡格列净 洛塞那肽 2型糖尿病 YKL-40 PPARγ 胰岛功能 [ |
| 英文关键词:canagliflozin losenatide type 2 diabetes YKL-40 PPARγ islet function |
| 基金项目: |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的研究卡格列净联合洛塞那肽对2型糖尿病胰岛素抵抗患者疗效,及对胰岛功能、血清YKL-40、过氧化物酶体增殖物激活受体γ(PPARγ)的影响。 方法选择2型糖尿病患者98例,随机均分为对照组(洛塞那肽治疗)和联合组(卡格列净联合洛塞那肽治疗),比较两组临床疗效、胰岛功能、血清YKL-40、PPARγ水平、血糖指标及不良反应发生率。 结果联合组治疗总有效率高于对照组(P＜0.05)。两组不良反应总发生率比较差异无显著性(P＞0.05)。与治疗前比较,两组治疗后胰岛素曲线下面积、胰岛β细胞功能指数、PPARγ升高,胰岛素抵抗指数、YKL-40、空腹血糖、2 h餐后血糖、糖化血红蛋白、体质指数降低；且联合组变化更为显著(P＜0.05)。 结论卡格列净联合洛塞那肽治疗可有效提高2型糖尿病胰岛素抵抗患者胰岛功能,并显著改善YKL-40、PPARγ水平。 |
| 英文摘要: |
| AimTo study the efficacy of canagliflozin combined with losenatide in the treatment of insulin resistance in type 2 diabetes patients, as well as the effect on pancreatic islet function, serum YKL-40, peroxisome proliferator activated receptor γ (PPARγ). Methods98 patients with type 2 diabetes were randomly divided into a control group (treated with losenatide) and a combination group (treated with canagliflozin and losenatide). The clinical efficacy, islet function, serum YKL-40 and PPARγ levels, blood glucose indicators, and incidence of adverse reactions of the two groups were compared. ResultsThe total effective rate of the combination group was higher than that of the control group (P＜0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). Compared with before treatment, the area under the insulin curve, pancreatic β cell function index, PPARγ in both groups after treatment were increased, where as insulin resistance index, YKL-40, fasting blood glucose, 2 hour postprandial blood glucose, glycated hemoglobin, and body mass index were increased, and the combined group showed more significant changes (P＜0.05). ConclusionCanagliflozin combined with losenatide can effectively improve the islet function of insulin resistance patients with type 2 diabetes mellitus, and significantly improve YKL-40 and PPARγ Level, which is worth of recommending. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|